Spark Therapeutics, Inc. (NASDAQ:ONCE) – Investment analysts at William Blair raised their FY2021 earnings per share (EPS) estimates for shares of Spark Therapeutics in a research report issued on Monday. William Blair analyst R. Prasad now anticipates that the biotechnology company will earn $0.25 per share for the year, up from their previous forecast of $0.20.
Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.75) by ($0.14). Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The company had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.33 million. During the same period in the previous year, the firm earned ($1.04) earnings per share. The firm’s quarterly revenue was up 14.7% on a year-over-year basis.
Several other research firms have also commented on ONCE. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $111.00 target price on shares of Spark Therapeutics in a report on Friday, October 6th. BMO Capital Markets set a $89.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 10th. Cowen and Company reiterated a “buy” rating and set a $95.00 price target on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Raymond James Financial, Inc. began coverage on Spark Therapeutics in a research report on Thursday, October 12th. They set an “outperform” rating and a $96.00 price target on the stock. Finally, Barclays PLC increased their price target on Spark Therapeutics from $104.00 to $107.00 and gave the stock an “overweight” rating in a research report on Friday, October 13th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $90.47.
In other news, insider Daniel Faga sold 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 19th. The stock was sold at an average price of $85.00, for a total value of $127,500.00. Following the transaction, the insider now owns 1,500 shares in the company, valued at $127,500. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Katherine A. High sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 26th. The shares were sold at an average price of $86.16, for a total value of $430,800.00. Following the completion of the transaction, the insider now owns 215,000 shares in the company, valued at approximately $18,524,400. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,090,850 shares of company stock worth $91,901,774. Company insiders own 7.30% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System lifted its position in shares of Spark Therapeutics by 22.7% in the third quarter. State Board of Administration of Florida Retirement System now owns 10,064 shares of the biotechnology company’s stock valued at $897,000 after acquiring an additional 1,860 shares in the last quarter. Pictet Asset Management Ltd. lifted its position in shares of Spark Therapeutics by 186.7% in the third quarter. Pictet Asset Management Ltd. now owns 131,471 shares of the biotechnology company’s stock valued at $11,722,000 after acquiring an additional 85,607 shares in the last quarter. Aperio Group LLC purchased a new position in shares of Spark Therapeutics in the third quarter valued at approximately $274,000. First Trust Advisors LP purchased a new position in shares of Spark Therapeutics in the third quarter valued at approximately $615,000. Finally, Nationwide Fund Advisors lifted its position in shares of Spark Therapeutics by 8.6% in the third quarter. Nationwide Fund Advisors now owns 21,028 shares of the biotechnology company’s stock valued at $1,875,000 after acquiring an additional 1,659 shares in the last quarter. Institutional investors and hedge funds own 77.29% of the company’s stock.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.